Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03619174Not ApplicableCompleted

LIBERATE International

Role: lead

NCT04206085Not ApplicableCompleted

Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence

Role: lead

NCT04720352Not ApplicableUnknown

Prospective US Radiofrequency SUI Trial

Role: lead

NCT03479229Not ApplicableCompleted

Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy

Role: lead

NCT03679702Not ApplicableUnknown

A Viveve Experience Normalizes Untreated Selective Serotonin Reuptake Inhibitor (SSRI) Sexuality Syndrome

Role: collaborator

NCT02261974Not ApplicableCompleted

VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness

Role: lead

All 6 trials loaded